Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Non Operating Income (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Non Operating Income for 10 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 136.56% year-over-year to $4.7 million, compared with a TTM value of $1.3 million through Dec 2025, up 211.4%, and an annual FY2025 reading of $1.3 million, up 211.4% over the prior year.
  • Non Operating Income was $4.7 million for Q4 2025 at Heron Therapeutics, up from -$2.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.7 million in Q4 2025 and bottomed at -$6.9 million in Q2 2022.
  • Average Non Operating Income over 5 years is -$415368.4, with a median of -$500000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income crashed 1156.59% in 2022, then surged 455.25% in 2024.
  • Year by year, Non Operating Income stood at -$1.1 million in 2021, then skyrocketed by 143.82% to $486000.0 in 2022, then crashed by 116.26% to -$79000.0 in 2023, then skyrocketed by 2596.2% to $2.0 million in 2024, then surged by 136.56% to $4.7 million in 2025.
  • Business Quant data shows Non Operating Income for HRTX at $4.7 million in Q4 2025, -$2.1 million in Q3 2025, and -$744000.0 in Q2 2025.